Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors

Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus

Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,860

TGFβ in Cancer

Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907

A small molecule–kinase interaction map for clinical kinase inhibitors

Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923

Valvular heart disease associated with fenfluramine-phentermine

Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632

TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes

Sanford, L. P., Ormsby, I., Groot, A. C. G.-D., Sariola, H., Friedman, R., Boivin, G. P., Cardell, E. L., & Doetschman, T. (1997) · Development · doi:10.1242/dev.124.13.2659 · Cited by 1,447

TGFβ: the molecular Jekyll and Hyde of cancer

Bierie, B., & Moses, H. L. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1926 · Cited by 1,291

Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease

Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 882

Physiological Actions and Clinical Applications of Transforming Growth Factor-β (TGF-β)

Roberts, A. B., & Sporn, M. B. (1993) · Growth Factors · doi:10.3109/08977199309029129 · Cited by 755

Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation

Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 714

Transforming Growth Factor-β Signaling Through the Smad Pathway: Role in Extracellular Matrix Gene Expression and Regulation

Verrecchia, F., & Mauviel, A. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01641.x · Cited by 683

Transforming Growth Factor-β Signaling in Immunity and Cancer

Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366

Targeting the TGFβ signalling pathway in disease

Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466

Targeting TGF-β Signaling in Cancer

Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944

Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer

Du, B., & Shim, J. S. (2016) · Molecules · doi:10.3390/molecules21070965 · Cited by 829

Navigating CAR-T cells through the solid-tumour microenvironment

Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 580

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Lahn, M. M. F., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 571

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 502

Big opportunities for small molecules in immuno-oncology

Adams, J. L., Smothers, J. F., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 492

Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis

Jackstadt, R., van Hooff, S. R., Leach, J. D. G., Cortés-Lavaud, X., Lohuis, J. O., Ridgway, R. A., Wouters, V. M., Roper, J., Kendall, T. J., Roxburgh, C. S. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.003 · Cited by 438

Overcoming TGFβ-mediated immune evasion in cancer

Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377

TGF-β Signaling in Control of Cardiovascular Function

Goumans, M.-J., & ten Dijke, P. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022210 · Cited by 360

Transforming growth factor-β in myocardial disease

Frangogiannis, N. G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00646-w · Cited by 352

Epithelial–mesenchymal transition: a new target in anticancer drug discovery

Marcucci, F., Stassi, G., & Maria, R. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 345

The fibrosis-cell death axis in heart failure

Piek, A., de Boer, R. A., & Silljé, H. H. W. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9536-9 · Cited by 308

TGF ‐β as a driver of fibrosis: physiological roles and therapeutic opportunities

Budi, E. H., Schaub, J. R., Decaris, M. L., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 310

TGFβ inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence

Bird, T. G., Müller, M., Boulter, L., Vincent, D. F., Ridgway, R. A., Lopez-Guadamillas, E., Lu, W.-Y., Jamieson, T., Govaere, O., Campbell, A. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan1230 · Cited by 261

Clinical development of therapies targeting TGFβ: current knowledge and future perspectives

Ciardiello, D., Élez, E., Tabernero, J. M., & Seoane, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.009 · Cited by 279

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma

Zhao, Y., Cao, J., Melamed, A., Worley, M. J., Gockley, A. A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 265

Targeting TGF-β Signaling for Therapeutic GainPreprint

Akhurst, R. J. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022301 · Cited by 255

First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1380 · Cited by 239

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

Martin, C. J., Datta, A., Littlefield, C., Kalra, A., Chapron, C., Wawersik, S., Dagbay, K. B., Brueckner, C. T., Nikiforov, A., Danehy, F. T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8456 · Cited by 224

On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?

Teixeira, A. F., ten Dijke, P., & Zhu, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00605 · Cited by 216

Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF

Mercer, P. F., Woodcock, H. V., Eley, J. D., Platé, M., Sulikowski, M. G., Durrenberger, P. F., Franklin, L., Nanthakumar, C. B., Man, Y., Genovese, F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207429 · Cited by 206

Dissecting fibrosis: therapeutic insights from the small-molecule toolbox

Nanthakumar, C. B., Hatley, R. J. D., Lemma, S., Gauldie, J., Marshall, R. P., & Macdonald, S. J. F. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4592 · Cited by 211

Current and upcoming therapies to modulate skin scarring and fibrosis

Coentro, J. Q., Pugliese, E., Hanley, G., Raghunath, M., & Zeugolis, D. I. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.009 · Cited by 207

TGF-β Signaling in Liver, Pancreas, and Gastrointestinal Diseases and Cancer

Gough, N. R., Xiang, X., & Mishra, L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.064 · Cited by 208

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?

Sweeney, M., Corden, B., & Cook, S. A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910865 · Cited by 201

Molecular and Cellular Aspects of Calcific Aortic Valve Disease

Towler, D. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.300155 · Cited by 197

Targeting transforming growth factor-β receptors in pulmonary hypertension

Guignabert, C., & Humbert, M. J. C. (2020) · European Respiratory Journal · doi:10.1183/13993003.02341-2020 · Cited by 203

Human cardiac fibrosis-on-a-chip model recapitulates disease hallmarks and can serve as a platform for drug testing

Mastikhina, O., Moon, B., Williams, K., Hatkar, R., Gustafson, D., Mourad, O., Sun, X., Koo, M., Lam, A. Y. L., Sun, Y., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119741 · Cited by 192

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first‐in‐class transforming growth factor‐β receptor type I inhibitor

Yingling, J. M., McMillen, W. T., Yan, L., Huang, H., Sawyer, J. S., Graff, J., Clawson, D. K., Britt, K. S., Anderson, B. D., Beight, D. W., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23795 · Cited by 187

Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis

Wei, Y., Kim, T. J., Peng, D. H., Duan, D., Gibbons, D. L., Yamauchi, M., Jackson, J., Saux, C. J. L., Calhoun, C., Peters, J. I., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94624 · Cited by 185

TGF-β-induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies

Ong, C. H., Tham, C. L., Harith, H. H., Firdaus, N., & Israf, D. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174510 · Cited by 204

Eliminating METTL1‐mediated accumulation of PMN‐MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation

Zeng, X., Liao, G., Li, S., Liu, H., Zhao, X. H., Li, S., Lei, K., Zhu, S., Chen, Z., Zhao, Y., et al. (2022) · Hepatology · doi:10.1002/hep.32585 · Cited by 188

Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)

Cho, E. S., Kang, H. E., Kim, N. H., & Yook, J. I. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-018-01108-7 · Cited by 182

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment

Gulley, J. L., Schlom, J., Barcellos‐Hoff, M. H., Wang, X., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., & Moustakas, A. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13146 · Cited by 182

A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment

Huynh, L., Hipolito, C. J., & ten Dijke, P. (2019) · Biomolecules · doi:10.3390/biom9110743 · Cited by 177

Discovery of N -((4-([1,2,4]Triazolo[1,5- a ]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1 H -imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent

Jin, C. H., Krishnaiah, M., Sreenu, D., Subrahmanyam, V. B., Rao, K. S., Lee, H. J., Park, S., Park, H., Lee, K., Sheen, Y. Y., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500115w · Cited by 168

Development of an ALK2-Biased BMP Type I Receptor Kinase Inhibitor

Mohedas, A. H., Xing, X., Armstrong, K. A., Bullock, A. N., Cuny, G. D., & Yu, P. B. (2013) · ACS Chemical Biology · doi:10.1021/cb300655w · Cited by 164

Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling

Parichatikanond, W., Luangmonkong, T., Mangmool, S., & Kurose, H. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00034 · Cited by 160

Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer

Stüber, T. N., Monjezi, R., Wallstabe, L., Kühnemundt, J., Nietzer, S., Dandekar, G., Wöckel, A., Einsele, H., Wischhusen, J., & Hudecek, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000676 · Cited by 151

Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors

Zheng, Y., Tang, L., Mabardi, L., Kumari, S., & Irvine, D. J. (2017) · ACS Nano · doi:10.1021/acsnano.7b00078 · Cited by 145

A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension

Yung, L., Nikolić, I., Paskin-Flerlage, S. D., Pearsall, R. S., Kumar, R., & Yu, P. B. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-1955oc · Cited by 146

Intracellular and extracellular TGF-β signaling in cancer: some recent topics

Miyazono, K., Katsuno, Y., Koinuma, D., Ehata, S., & Morikawa, M. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0646-8 · Cited by 145

TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective

Nixon, B. G., Gao, S., Wang, X., & Li, M. O. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00796-z · Cited by 144

TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis

Sun, T., Huang, Z., Liang, W.-C., Yin, J., Lin, W. Y., Wu, J., Vernes, J.-M., Lutman, J., Caplazi, P., Jeet, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0407 · Cited by 134

Targeting immunosuppression by TGF-β1 for cancer immunotherapy

de Streel, G., & Lucas, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114697 · Cited by 131

Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFβ signaling through TGFBR1 stabilization

Lee, T.-H., Yeh, C., Lee, Y.-T., Shih, Y.-C., Chen, Y.-T., Hung, C., You, M.-Y., Wu, P., Shentu, T., Huang, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18047-x · Cited by 131

Characterization and Validation of a Human 3D Cardiac Microtissue for the Assessment of Changes in Cardiac Pathology

Archer, C. R., Sargeant, R., Basak, J., Pilling, J. E., Barnes, J. R., & Pointon, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-28393-y · Cited by 126

Mechanisms of Normal Tissue Injury From Irradiation

Citrin, D. E., & Mitchell, J. B. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.04.001 · Cited by 126

TGFβ, smooth muscle cells and coronary artery disease: a review

Low, E. L., Baker, A. H., & Bradshaw, A. C. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.09.004 · Cited by 127

Isorhamnetin Inhibits Liver Fibrosis by Reducing Autophagy and Inhibiting Extracellular Matrix Formation via the TGF-β1/Smad3 and TGF-β1/p38 MAPK Pathways

Liu, N., Feng, J., Lu, X., Yao, Z., Liu, Q., Lv, Y., Han, Y., Deng, J., & Zhou, Y. (2019) · Mediators of Inflammation · doi:10.1155/2019/6175091 · Cited by 123

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment

Hanks, B. A., Holtzhausen, A., Evans, K. S., Jamieson, R., Gimpel, P., Campbell, O. M., Hector-Greene, M., Sun, L., Tewari, A. K., George, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65745 · Cited by 123

Cancer Immunotherapy: Selected Targets and Small‐Molecule Modulators

Weinmann, H. (2016) · ChemMedChem · doi:10.1002/cmdc.201500566 · Cited by 122

Integrin αvβ8–expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells

Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119

Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy

Zhao, H., Wei, J., & Sun, J. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107101 · Cited by 118

Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation

Shen, Y., Lu, C., Song, Z., Qiao, C., Wang, J., Chen, J., Zhang, C., Zeng, X., Ma, Z., Chen, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31141-6 · Cited by 123

Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity

Zhou, Y., Shen, G., Zhou, X., & Li, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02242-7 · Cited by 130

Endoplasmic reticulum protein TXNDC5 promotes renal fibrosis by enforcing TGF-β signaling in kidney fibroblasts

Chen, Y., Jhao, P.-Y., Hung, C., Wu, Y., Lin, S., Chiang, W., Lin, S., & Yang, K. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143645 · Cited by 114

Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5

Engebretsen, K. V. T., Skårdal, K., Bjørnstad, S., Marstein, H. S., Skrbic, B., Sjaastad, I., Christensen, G., Bjørnstad, J. L., & Tønnessen, T. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.08.008 · Cited by 110

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Kovacs, R. J., Maldonado, G., Azaro, A., Fernández, M. S., Romero, F. L., Sepulveda-Sánchez, J. M., Corretti, M., Carducci, M., Dolan, M., Gueorguieva, I., et al. (2015) · Cardiovascular Toxicology · doi:10.1007/s12012-014-9297-4 · Cited by 108

Non-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and Mouse

Berridge, B. R., Mowat, V., Nagai, H., Nyska, A., Okazaki, Y., Clements, P., Rinke, M., Snyder, P. W., Boyle, M. C., & Wells, M. Y. (2016) · Journal of Toxicologic Pathology · doi:10.1293/tox.29.3s-1 · Cited by 106

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Fujiwara, Y., Nokihara, H., Yamada, Y., Yamamoto, N., Sunami, K., Utsumi, H., Asou, H., Takahashi, O., Ogasawara, K., Gueorguieva, I., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2895-4 · Cited by 101

A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys

Mitra, M. S., Lancaster, K., Adedeji, A. O., Palanisamy, G. S., Dave, R. A., Zhong, F., Holdren, M. S., Turley, S. J., Liang, W., Wu, Y., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa024 · Cited by 104

Transforming growth factor β and its role in heart disease

Liu, G., Ma, C., Yang, H., & Zhang, P.-Y. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4246 · Cited by 97

Immunotherapy for advanced hepatocellular carcinoma, where are we?

Li, Z., Ding, J., Li, H., Wang, Z., & Wu, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188441 · Cited by 95

Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor–Prolyl Hydroxylase Inhibitor for Anemia

Ariazi, J. L., Duffy, K. J., Adams, D. F., Fitch, D. M., Luo, L., Pappalardi, M. B., Biju, M. P., DiFilippo, E. H., Shaw, T., Wiggall, K., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242503 · Cited by 94

Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease

Minagawa, S., Lou, J., Seed, R. I., Cormier, A., Wu, S., Cheng, Y., Murray, L., Tsui, P., Connor, J., Herbst, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008074 · Cited by 90

Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges

Wu, B., Sodji, Q. H., & Oyelere, A. K. (2022) · Cancers · doi:10.3390/cancers14030552 · Cited by 92

Targeting small molecule drugs to T cells with antibody-directed cell-penetrating gold nanoparticles

Yang, Y.-S. S., Moynihan, K. D., Bekdemir, A., Dichwalkar, T., Noh, M. M., Watson, N., Melo, M. B., Ingram, J. R., Suh, H., Ploegh, H. L., et al. (2018) · Biomaterials Science · doi:10.1039/c8bm01208c · Cited by 86

Transforming growth factor-β receptors: versatile mechanisms of ligand activation

Chia, Z.-J., Cao, Y., Little, P. J., & Kamato, D. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01235-6 · Cited by 91

TGFβ signaling pathways in human health and disease

Chen, P., Qin, L., & Simons, M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1113061 · Cited by 89

TGF-β signaling networks in the tumor microenvironment

Chan, M. K.-K., Chung, J. Y.-F., Tang, P. C.-T., Chan, A. S.-W., Ho, J. Y.-Y., Lin, T. P.-T., Chen, J., Leung, K.-T., To, K.-F., Lan, H.-Y., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215925 · Cited by 90

Physiological, pharmacological and toxicological considerations of drug‐induced structural cardiac injury

Cross, M. J., Berridge, B. R., Clements, P., Cove-Smith, L., Force, T. L., Hoffmann, P., Holbrook, M., Lyon, A. R., Mellor, H. R., Norris, A. A., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12979 · Cited by 81

TGFβ signaling networks in ovarian cancer progression and plasticity

Kumari, A., Shonibare, Z., Monavarian, M., Arend, R. C., Lee, N. Y., Inman, G. J., & Mythreye, K. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10077-z · Cited by 78

Defining a therapeutic window for the novel TGF ‐β inhibitor LY 2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Gueorguieva, I., Cleverly, A., Stauber, A. J., Pillay, N. S., Rodon, J. A., Miles, C., Yingling, J. M., & Lahn, M. M. F. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12256 · Cited by 78

Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma

Li, N., Rodriguez, J. L., Yin, Y., Logun, M. T., Zhang, L., Yu, S., Hicks, K., Zhang, J. V., Zhang, L., Xie, C., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.020 · Cited by 81

Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression

van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 77

IL-13Rα2/TGF- β bispecific CAR-T cells counter TGF- β -mediated immune suppression and potentiate anti-tumor responses in glioblastoma

Hou, A. J., Shih, R. M., Uy, B. R., Shafer, A. M., Chang, Z. L., Comin-Anduix, B., Güemes, M., Galić, Z., Phyu, S. M., Okada, H., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae126 · Cited by 81

Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways

Li, T., Zhao, N., Lu, J., Zhu, Q., Liu, X., Hao, F., & Jiao, X. (2019) · Bioengineered · doi:10.1080/21655979.2019.1632669 · Cited by 72

Targeting epithelial–mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring

Bhatia, S., Monkman, J. H., Toh, A. K. L., Nagaraj, S. H., & Thompson, E. W. (2017) · Biochemical Journal · doi:10.1042/bcj20160782 · Cited by 76

The Role of Breast Cancer Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy

Scioli, M. G., Storti, G., D’Amico, F., Gentile, P., Fabbri, G., Cervelli, V., & Orlandi, A. (2019) · Cancers · doi:10.3390/cancers11071021 · Cited by 71

TGF ‐β superfamily co‐receptors in cancer

Pawlak, J. B., & Blobe, G. C. (2021) · Developmental Dynamics · doi:10.1002/dvdy.338 · Cited by 68

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants

Maden, C. H., Fairman, D., Chalker, M., Costa, M. J., Fahy, W. A., Garman, N., Lukey, P. T., Mant, T., Parry, S., Simpson, J. K., et al. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2435-3 · Cited by 66

Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy

Tschernia, N. P., & Gulley, J. L. (2022) · BioDrugs · doi:10.1007/s40259-022-00521-1 · Cited by 61

Principles of the activin receptor signaling pathway and its inhibition

Lodberg, A. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.04.001 · Cited by 63

Good and bad sides of TGFβ-signaling in myocardial infarction

Euler, G. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00066 · Cited by 62

Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy

Zhou, Q., Li, Y., Zhu, Y., Yu, C., Jia, H., Bao, B., Hu, H., Xiao, C., Zhang, J., Zeng, X., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.026 · Cited by 63

Epigenetic Reprogramming of TGF-β Signaling in Breast Cancer

Suriyamurthy, S., Baker, D. A., ten Dijke, P., & Iyengar, P. V. (2019) · Cancers · doi:10.3390/cancers11050726 · Cited by 63

In the Shadow of Fibrosis: Innate Immune Suppression Mediated by Transforming Growth Factor-β

Thomas, B. J., Kan‐o, K., Loveland, K. L., Elias, J. A., & Bardin, P. G. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0248ps · Cited by 62

Fibroblasts orchestrate cellular crosstalk in the heart through the ECM

Bowers, S., Meng, Q., & Molkentin, J. D. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00043-7 · Cited by 59

Biological approaches for hypertrophic scars

Zhong, L.-Z., Li, M.-R., & Fu, X.-B. (2019) · International Wound Journal · doi:10.1111/iwj.13286 · Cited by 50

Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer

Busenhart, P., Montalban‐Arques, A., Katkeviciutė, E., Morsy, Y., Passen, C. V., Hering, L., Atrott, K., Lang, S., Garzon, J. F. G., Naschberger, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003465 · Cited by 59

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade

Greco, R., Qu, H., Qu, H., Theilhaber, J., Shapiro, G., Gregory, R. C., Winter, C. G., Malkova, N. V., Sun, F. F., Jaworski, J. A., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1811605 · Cited by 58

Role of IL-17A in murine models of COPD airway disease

Yanagisawa, H., Hashimoto, M., Minagawa, S., Takasaka, N., Ma, R., Moermans, C., Ito, S., Araya, J., Budelsky, A., Goodsell, A., et al. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00301.2016 · Cited by 60

Different roles of interleukin 6 and interleukin 11 in the liver: implications for therapy

Widjaja, A. A., Chothani, S. P., & Cook, S. A. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1761203 · Cited by 55

MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine

Smith, B., Agarwal, P., & Bhowmick, N. A. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0525 · Cited by 56

Development of small molecule inhibitors targeting TGF-β ligand and receptor: Structures, mechanism, preclinical studies and clinical usage

Wang, H., Chen, M., Sang, X., You, X., Wang, Y., Paterson, I. C., Hong, W., & Yang, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112154 · Cited by 56

Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies

Harryvan, T. J., Verdegaal, E. M. E., Hardwick, J. C. H., Hawinkels, L. J. A. C., & van der Burg, S. H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111989 · Cited by 55

The effect of transforming growth factor-beta type I receptor kinase inhibition on the heart valves of Sprague-Dawley rats

Maratea, K. A. (2009) · Purdue e-Pubs (Purdue University System)

A Constitutive Mutation ofALK5Disrupts Cardiac Looping and Morphogenesis in Mice

Charng, M., Frenkel, P. A., Lin, Q., Yumada, M., Schwartz, R. J., Olson, E. N., Overbeek, P. A., & Schneider, M. D. (1998) · Developmental Biology · doi:10.1006/dbio.1998.8905 · Cited by 40

Inhibition of ALK5 Signaling Induces Physeal Dysplasia in Rats

Frazier, K. S., Thomas, R. A., Scicchitano, M. S., Mirabile, R. C., Boyce, R. W., Zimmerman, D. M., Grygielko, E. T., Nold, J. B., DeGouville, A.-C., Huet, S., et al. (2007) · Toxicologic Pathology · doi:10.1080/01926230701198469 · Cited by 49

Signaling via the Tgf-β type I receptor Alk5 in heart development

Sridurongrit, S., Larsson, J., Schwartz, R. J., Ruiz‐Lozano, P., & Kaartinen, V. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2008.07.038 · Cited by 158

Activin receptor-like kinase 2 and Smad6 regulate epithelial–mesenchymal transformation during cardiac valve formation

Desgrosellier, J. S., Mundell, N. A., McDonnell, M. A., Moses, H. L., & Barnett, J. V. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2004.12.037 · Cited by 88